Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
MG Rodriquenz, D Ciardiello, TP Latiano… - Critical Reviews in …, 2022 - Elsevier
Abstract Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC)
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
MG Rodriquenz, D Ciardiello, TP Latiano… - CRITICAL REVIEWS …, 2022 - iris.unicampania.it
Abstract Approximatively 8–15% of patients with metastatic colorectal cancer (mCRC)
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better …
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.
MG Rodriquenz, D Ciardiello, TP Latiano… - Critical Reviews in …, 2022 - europepmc.org
Approximatively 8-15% of patients with metastatic colorectal cancer (mCRC) harbor
mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge …
mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge …
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer
MG Rodriquenz, D Ciardiello… - Critical reviews in …, 2022 - pubmed.ncbi.nlm.nih.gov
Approximatively 8-15% of patients with metastatic colorectal cancer (mCRC) harbor
mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge …
mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge …